<DOC>
	<DOC>NCT00063206</DOC>
	<brief_summary>Primary: To compare the antidepressant efficacy and safety of subjects receiving DVS-233 SR versus subjects receiving placebo. Secondary: To assess the response of subjects receiving DVS-233 SR for the clinical global evaluation, functionality, general well-being, pain, and remission (Hamilton Psychiatric Rating Scale for Depression, 17-item [HAM-D&lt;sub&gt;17&lt;/sub&gt;] &lt; 7) versus those subjects receiving placebo.</brief_summary>
	<brief_title>Study Evaluating DVS-233 in Adult Outpatients With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<criteria>Subjects must have a primary diagnosis of major depressive disorder (MDD) Depressive symptoms for at least 30 days prior to the screening visit Minimum screening and study day 1 (baseline) scores of 20 on the Hamilton Psychiatric Rating Scale for Depression (HAM D&lt;sub&gt;17&lt;/sub&gt;) Treatment with DVS233 SR at any time in the past Treatment with venlafaxine (immediate release [IR] or extended release [ER]) within 90 days of study day 1 Known hypersensitivity to venlafaxine (IR or ER)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Depressive Disorder, Major</keyword>
	<keyword>Depression, Involutional</keyword>
</DOC>